Protalix BioTherapeutics Inc (AMEX:PLX)’s traded shares stood at 0.87 million during the last session, with the company’s beta value hitting -0.16. At the close of trading, the stock’s price was $1.62, to imply a decrease of -1.82% or -$0.03 in intraday trading. The PLX share’s 52-week high remains $3.10, putting it -91.36% down since that peak but still an impressive 49.38% since price per share fell to its 52-week low of $0.82.

Protalix BioTherapeutics Inc (AMEX:PLX) trade information

After registering a -1.82% downside in the last session, Protalix BioTherapeutics Inc (PLX) has traded red over the past five days. The 5-day price performance for the stock is -2.99%, and -44.90% over 30 days. With these gigs, the year-to-date price performance is -13.83%.

PLX Dividends

Protalix BioTherapeutics Inc has its next earnings report out in June. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

The next major institution holding the largest number of shares is RENAISSANCE TECHNOLOGIES LLC with 0.8 million shares, or about 1.1016% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $0.94 million.

We also have Unified Series Trust-AUER GROWTH FUND and Bridgeway Funds, Inc.-Ultra-Small Company Market Fund as the top two Mutual Funds with the largest holdings of the Protalix BioTherapeutics Inc (PLX) shares. Going by data provided on Mar 31, 2025 , Unified Series Trust-AUER GROWTH FUND holds roughly 200.0 shares. This is just over 0.25% of the total shares, with a market valuation of $0.32 million. Data from the same date shows that the other fund manager holds a little less at 180.0, or 0.23% of the shares, all valued at about 0.29 million.